Document text
Principal Investigator: Eliezer Masliah
Organization: NATIONAL INSTITUTE ON AGING
Fiscal Year: 2024
Award: $83,018
Funding agency: National Institute on Aging
The MNU at the LNG is to harness the immune system to better understand the mechanisms of neurodegeneration and to develop therapies for synucleinopathies of the aging population such as DLB, PD and AD. We propose 3 Aims, the first investigating the role of innate immune responses and combinatorial immunotherapy targeting LRRK2, Toll-like receptors, p38, NFAT and the protein aggregates (eg: syn, Abeta, tau) in PD/DLB; the second assessing downstream pro-inflammatory signaling pathways including MAPK-p38, NFAT and NFkB and the third evaluating the role of aging in T cell mediated adaptive immune cell responses in PD/DLB pathogenesis and for developing immunotherapies for synucleinopathies. During this period, we published 9 manuscripts mostly focusing understanding the pathogenesis of PD/DLB and developing novel pharmacological and immunotherapeutical approaches.
Progress for Aim1. In previous studies we identified several immune receptors that mediate neuroinflammation in synucleinopathies, including Toll-like receptor 2 (TLR2) and have shown which species of syn bind TLR2 and mediates neuroinflammation. We were interested at better characterizing the downstream pathways mediating neurodegeneration by using multiomics approaches. For this purpose, we collaborated with Dr. Jung laboratory in South Korea. First, we establish transcriptomic and epigenomic landscapes of the substantia nigra by profiling 113,207 nuclei obtained from healthy controls and patients with PD. Our multiomics data integration provides cell type annotation of 128,724 cis-regulatory elements (cREs) and uncovers cell type-specific dysregulations in cREs with a strong transcriptional influence on genes implicated in PD. The establishment of high-resolution three-dimensional chromatin contact maps identifies 656 target genes of dysregulated cREs and genetic risk loci, uncovering both potential and known PD risk genes. Notably, these candidate genes exhibit modular gene expression patterns with unique molecular signatures in distinct cell types, highlighting altered molecular mechanisms in immune cells like microglia as well as in oligodendroglial cells (Lee et al, Sci Adv 2023). In addition, mice treated with LV-shRNA α-syn had amelioration of abnormal microglial activation and astrocytosis in AD mice. This suggests a link between Aβ and α-syn in pathology pointing to a possible therapeutic angle for AD targeting α-syn. This paper was published in JAD (Leitao et al JAD 2023). In other studies, in collaboration with the Cookson lab we studied the distribution of p-a-synuclein in control and PD brains using the PLA method (Arlinghaus et al J Park Dis 2023) and more recently spatial transcriptomics studies in the brains of a-synuclein tg mice and DLB brains (Horan-Portelance et sl BioRvix 2024).
Progress for Aim 2. We previously showed that once extracellular -syn binds TLR2, (Kim et al Science TM 2020) LRRK2 promoted a neuroinflammatory cascade by selectively phosphorylating and inducing nuclear translocation of the immune transcription factor nuclear factor of activated T cells, cytoplasmic 2 (NFATc2). Our results suggest that modulation of LRRK2 and its downstream signaling mediator NFATc2 might be therapeutic targets for treating synucleinopathies. Next in collaboration with the Gerez lab in Germany we investigated the propagation effects of syn in a novel reporter model. Expression of the secreted syn in the mouse brain was under the control of a novel hybrid promoter in combination with adeno-associated virus serotype 9 (AAV9). The secreted syn is aggregation-prone and amyloidogenic, and when expressed in the brain of wild-type non-transgenic mice, it induces a Parkinson's disease-like phenotype that includes a robust syn pathology in the substantia nigra, neuronal loss, neuroinflammation, and motor deficits, all the key features of experimental animal models of DLB/PD ( Gerez et al NPJ Parkinson’s Disease 2024). Finally, we investigated the role of p38 MAPK as a potential immunomodulatory pathway. We hypothesized that p38α might be associated with neuronal p38γ distribution and synaptic dysfunction in these diseases. We found that inhibition of p38α reduced neuroinflammation and ameliorated synaptic, neurodegenerative, and motor behavioral deficits in transgenic mice overexpressing human α-syn. Moreover, treatment with SKF-86002 promoted the redistribution of p38γ to synapses and reduced the accumulation of α-syn in mice overexpressing human α-syn. Supporting the potential value of targeting p38 in DLB/PD, we found that SKF-86002 promoted the redistribution of p38γ in neurons differentiated from iPS cells derived from patients with familial PD (carrying the A53T α-syn mutation) and healthy controls. These findings provide a mechanistic connection between p38α and p38γ as well as a rationale for targeting this pathway in DLB/PD. This study was recently published in Science Translational Medicine (Iba et al Science TM 2023).
Progress for Aim 3. In collaboration with the Sen laboratory we showed that T cell infiltration with potential participation of NKT cells play an important role in DLB/PD. To evaluate the potential of targeting NKT cells to modulate neuroinflammation, we treated α-syn transgenic (tg) mice (e.g.: Thy1 promoter line 61) with an antibody against CD1d, which is a glycoprotein expressed in antigen presenting cells (APCs). CD1d-presented lipid antigens activate NKT cells through the interaction with T cell receptor in NKTs, resulting in the production of cytokines. Thus, we hypothesized that blocking the APC-NKT interaction with an anti-CD1d antibody might reduce neuroinflammation and neurodegeneration in models of DLB/PD. Treatment with the anti-CD1d antibody did not have effects on CD3 (T cells), slightly decreased CD4 and increased CD8 lymphocytes in the mice. Moreover, double labeling studies showed that compared to control (IgG) treated α-syn tg mice, treatment with anti-CD1d decreased numbers of CD3/interferon γ (IFN γ)-positive cells, consistent with NKTs. Further double labeling studies showed that CD1d-positive cells co-localized with the astrocytes marker GFAP and that anti-CD1d antibody reduced this effect. While in control α-syn tg mice CD3 positive cells were near astrocytes, this was modified by the treatment with the CD1d antibody. By qPCR, levels of IFN γ, CCL4, and interleukin-6 were increased in the IgG treated α-syn tg mice. Treatment with CD1d antibody blunted this cytokine response that was associated with reduced astrocytosis and microgliosis in the CNS of the α-syn tg mice treated with CD1d antibody. These results suggest that reducing infiltration of NKT cells with an antibody against CD1d might be a potential therapeutical approach for DLB/PD (Iba et al J Neuroinflammation 2024). Other experiments underway includes investigating the effects of aging and deleting microglia with the PLX3387 (a compound that targets CSF1R) on synucleinopathies in DLB/PD models. Microglial depletion also ameliorated neuronal and synaptic degeneration in -syn-tg mice, thereby resulted partially improving the motor behavioral deficit in syn-tg mice. We suggest that microglia play a critical role in the pathogenesis of synucleinopathies, and that modulation of microglial state might be an effective therapeutic strategy for synucleinopathies. We are also investigating the effects of aging and inflammation in models where T cells and microglia are deleted or where CSF1 and CSF2 are modulated, manuscripts for all these studies are under preparation.
Other collaborations at LNG are with Drs. Cookson, Singleton, Traynor and Scholz on the genetic architecture of FTD, DLB and MSA by providing expert neuropathological assessment, animal models and human tissues.
Terms: <2019 novel corona virus><2019 novel coronavirus><2019-nCoV><3-D><3-Dimensional><3D><7S Gamma Globulin><ACT2><AD dementia><AD related dementia><ADRD><AT744.1><Act-2><Adeno-Associated Viruses><Advanced Development><Aging><Alpha-Synuclein transgenic mouse><Alzheimer Type Dementia><Alzheimer beta-Protein><Alzheimer disease dementia><Alzheimer sclerosis><Alzheimer syndrome><Alzheimer's><Alzheimer's Amyloid beta-Protein><Alzheimer's Disease><Alzheimer's amyloid><Alzheimer's and related dementias><Alzheimer's disease and related dementia><Alzheimer's disease and related disorders><Alzheimer's disease or a related dementia><Alzheimer's disease or a related disorder><Alzheimer's disease or related dementia><Alzheimer's disease related dementia><Alzheimers Dementia><Amyloid Alzheimer's Dementia Amyloid Protein><Amyloid Beta-Peptide><Amyloid Protein A4><Amyloid beta-Protein><Amyloid β><Amyloid β-Peptide><Amyloid β-Protein><Animal Model><Animal Models and Related Studies><Animals><Antibodies><Antigen-Presenting Cells><Antigens><Apo-E><ApoE><ApoE protein><Apolipoprotein E><Astrocytes><Astrocytosis><Astrocytus><Astroglia><Astroprotein><Aβ><B cell differentiation factor><B cell stimulating factor 2><B-Cell Differentiation Factor><B-Cell Differentiation Factor-2><B-Cell Stimulatory Factor-2><BCDF><BSF-2><BSF2><Basal Transcription Factor><Basal transcription factor genes><Behavioral><Binding><Brain><Brain Nervous System><CCL4><CCL4 gene><CD115><CD115 Gene><CD3><CD3 Antigens><CD3 Complex><CD3 molecule><CD8 Cell><CD8 T cells><CD8 lymphocyte><CD8+ T cell><CD8+ T-Lymphocyte><CD8-Positive Lymphocytes><CD8-Positive T-Lymphocytes><COVID-19 virus><COVID19 virus><CSAID-Binding Protein 1><CSAID-Binding Protein 2><CSBP2><CSF1><CSF1 gene><CSF1R><CSF1R gene><CSF2><CSF2 gene><CSFMR><Candidate Disease Gene><Candidate Gene><Cell Aging><Cell Body><Cell Communication and Signaling><Cell Nucleus><Cell Senescence><Cell Signaling><Cell model><Cells><Cellular Aging><Cellular Senescence><Cellular model><Chemokine (C-C Motif) Ligand 4><Chemokine, CC Motif, Ligand 4><Chromatin><CoV-2><CoV2><Collaborations><Colony Stimulating Factor 1 Receptor Gene><Combination immunotherapy><Cytokine-Suppressive Antiinflammatory Drug-Binding Protein 1><Cytokine-Suppressive Antiinflammatory Drug-Binding protein 2><DNA Damage><DNA Injury><Dementia with Lewy Bodies><Dependoparvovirus><Dependovirus><Disease><Disorder><Dysfunction><Encephalon><Exhibits><Experimental Animal Model><Expression Signature><Extracellular Signal-Regulated Kinase Gene><Functional disorder><GEM model><GEMM model><GFA-Protein><GFAP><Gene Expression Profile><Gene Transcription><General Transcription Factor Gene><General Transcription Factors><Genes><Genetic Alteration><Genetic Change><Genetic Predisposition><Genetic Predisposition to Disease><Genetic Risk><Genetic Susceptibility><Genetic Transcription><Genetic defect><Genetic predisposing factor><Genetic propensity><Genetically Engineered Mouse><Germany><Glial Fibrillary Acid Protein><Glial Fibrillary Acidic Protein><Glial Intermediate Filament Protein><Gliosis><Glycoproteins><Goals><HPGF><Hepatocyte-Stimulating Factor><Hortega cell><Human><Hybridoma Growth Factor><Hybrids><IFN-Gamma><IFN-beta 2><IFN-g><IFN-γ><IFNB2><IFNG><IFNγ><IL-6><IL6 Protein><IMiD><IgG><Immune><Immune Activation 2><Immune Interferon><Immune Modulation Therapy><Immune mediated therapy><Immune modulatory therapeutic><Immune system><Immunes><Immunoglobulin Enhancer-Binding Protein><Immunoglobulin G><Immunologic Receptors><Immunological Receptors><Immunologically Directed Therapy><Immunomodulation><Immunotherapeutic agent><Immunotherapy><In Vitro><Infiltration><Inflammation><Inflammatory><Inflammatory Response><Inherited Predisposition><Inherited Susceptibility><Innate Immune Response><Innate Immunity><Interferon Gamma><Interferon Type II><Interleukin-6><Intracellular Communication and Signaling><Kinases><LB disease><LB disorder><LRRK2><LRRK2 gene><LRRK2 leucine-rich repeat kinase 2 gene><LRRK2 protein><Label><Laboratories><Lewy Body Disease><Lewy body disorder><Lewy disease><Lewy disorder><Link><Lipids><MAP Kinase Gene><MAPK><MAPK14><MAPK14 Mitogen-Activated Protein Kinase><MAPK14 gene><MCSF><MGC31930><MGI-2><MHC Receptor><MIP1B><MIP1B1><MT-bound tau><Macrophage Inflammatory Protein 1-Beta><Major Histocompatibility Complex Receptor><Manuscripts><Maps><Mediating><Mediator><Methods><Mice><Mice Mammals><Microglia><Mitogen-Activated Protein Kinase 14><Mitogen-Activated Protein Kinase Gene><Modeling><Modern Man><Molecular><Molecular Fingerprinting><Molecular Interaction><Molecular Profiling><Motor><Mouse Strains><Multiomic Data><Murine><Mus><Mutation><Mxi2><Myeloid Differentiation-Inducing Protein><NAC precursor><NF-AT><NF-AT proteins><NF-kB><NF-kappa B><NF-kappaB><NFAT proteins><NFAT-1><NFATC proteins><NFKB><Native Immunity><Natural Immunity><Nerve Cells><Nerve Degeneration><Nerve Unit><Neural Cell><Neurocyte><Neuroimmune><Neuroimmune system><Neuron Degeneration><Neuronal Differentiation><Neurons><Non-Specific Immunity><Nonspecific Immunity><Nuclear Factor kappa B><Nuclear Transcription Factor NF-kB><Nuclear Translocation><Nucleus><OKT3 antigen><PARK1 protein><PARK4 protein><PARK8 protein><Paper><Paralysis Agitans><Parkinson><Parkinson Disease><Parkinson disease 8 protein><Pathogenesis><Pathology><Pathway interactions><Patients><Phenotype><Phosphorylation><Phosphotransferase Gene><Phosphotransferases><Physiopathology><Plasmacytoma Growth Factor><Play><Predisposition gene><Preparation><Primary Parkinsonism><Primary Senile Degenerative Dementia><Production><Protein Phosphorylation><Proteins><Publishing><RNA Expression><Receptor Protein><Regulatory Element><Replicative Senescence><Reporter><Republic of Korea><Research><Resolution><Risk-associated variant><Role><SAPK2A><SARS corona virus 2><SARS-CO-V2><SARS-COVID-2><SARS-CoV-2><SARS-CoV2><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><SCYA4><SNCA><SNCA protein><Science><Serotyping><Severe Acute Respiratory Coronavirus 2><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome related corona virus 2><Signal Pathway><Signal Transduction><Signal Transduction Systems><Signaling><Small Inducible Cytokine A4><South Korea><Stress-Activated Protein Kinase 2A><Substantia Nigra><Substantia nigra structure><Susceptibility Gene><Synapses><Synaptic><System><T cell infiltration><T cell response><T-Cell Antigen Receptors><T-Cell Receptor><T-Cells><T-Lymphocyte><T3 Antigens><T3 Complex><T3 molecule><T8 Cells><T8 Lymphocytes><TAR DNA-binding protein 43><TDP-43><TDP43><TIL4><TLR protein><TLR2><TLR2 gene><TLR2 receptor><Testing><Therapeutic><Toll-Like Receptor 2><Toll-Like Receptor Family Gene><Toll-like receptors><Toll/Interleukin 1 Receptor-Like 4><Toll/Interleukin 1 Receptor-Like 4 Gene><Toll/Interleukin 1 Receptor-Like Protein 4><Transcription><Transcription Factor NF-kB><Transcription Factor Proto-Oncogene><Transcription factor genes><Transgenic Mice><Translational Research><Translational Science><Transphosphorylases><Wuhan coronavirus><a beta peptide><a-syn><a-syn transgenic mouse><a-synuclein><a-synuclein transgenic mouse><abeta><accessory cell><adaptive immunity><adeno associated virus group><age associated effects><age effect><age related effects><aged><aged group><aged groups><aged individual><aged individuals><aged people><aged person><aged persons><aged population><aged populations><aging effect><aging population><aging process><alpha synuclein><alpha synuclein gene><alpha-Syn Tg mouse><alpha-Syn transgenic mouse><alphaSP22><amyloid beta><amyloid-b protein><astrocytic glia><asyn><beta amyloid fibril><biological signal transduction><c-FMS><c-fms Genes><c-fms Proto-Oncogenes><cell type><combinatorial><combinatorial immunotherapy><compare to control><comparison control><conformer><coronavirus disease 2019 virus><coronavirus disease-19 virus><cytokine><cytoplasmic nuclear factor of activated T-cells><dardarin><dardarin gene><dardarin protein><data integration><develop therapy><dual immunotherapy><epigenomics><experiment><experimental research><experimental study><experiments><extracellular><gene expression pattern><gene expression signature><genetic architecture><genetic etiology><genetic mechanism of disease><genetic risk factor><genetic vulnerability><genetically engineered mouse model><genetically engineered murine model><genetically predisposed><genome mutation><gitter cell><glial activation><glial cell activation><hCoV19><human tissue><iPS><iPSC><iPSCs><immune drugs><immune modulating agents><immune modulating drug><immune modulating therapeutics><immune modulating therapies><immune modulation><immune modulatory agents><immune modulatory drugs><immune modulatory therapies><immune receptor><immune regulation><immune therapeutic approach><immune therapeutic interventions><immune therapeutic regimens><immune therapeutic strategy><immune therapy><immune-based therapeutics><immune-based therapies><immune-based treatments><immune-modulation treatment><immuno therapy><immunogen><immunologic reactivity control><immunologic therapeutics><immunomodulating agents><immunomodulating drugs><immunomodulation therapy><immunomodulation treatment><immunomodulator agent><immunomodulator drug><immunomodulator medication><immunomodulator prodrug><immunomodulator therapeutic><immunomodulator therapies><immunomodulator treatment><immunomodulator-based therapies><immunomodulatory><immunomodulatory agents><immunomodulatory drugs><immunomodulatory therapeutics><immunomodulatory therapies><immunomodulatory therapy><immunomodulatory treatment><immunoregulation><immunoregulatory><immunotherapeutics><immunotherapy agent><impact of age><improved><in vitro Model><in vivo Model><induced pluripotent cell><induced pluripotent stem cell><inducible pluripotent stem cell><influence of age><inherited factor><insoluble aggregate><interest><interferon beta 2><intervention development><kappa B Enhancer Binding Protein><lFN-Gamma><leucine-rich repeat kinase 2><member><mesoglia><microglial cell><microgliocyte><microtubule bound tau><microtubule-bound tau><model of animal><molecular profile><molecular signature><motor deficit><multiomics><multiple omic data><multiple omics><nCoV2><nerve cell death><nerve cell loss><neural degeneration><neural inflammation><neurodegeneration><neurodegenerative><neurogenetics><neuroinflammation><neuroinflammatory><neurological degeneration><neuron cell death><neuron cell loss><neuron death><neuron loss><neuronal><neuronal cell death><neuronal cell loss><neuronal death><neuronal degeneration><neuronal loss><neuropathologic><neuropathological><neuropathology><neurotoxic><non A-beta component of AD amyloid><non A4 component of amyloid precursor><novel><nuclear factor kappa beta><nuclear factors of activated T-cells><overexpress><overexpression><p38><p38 MAP Kinase><p38 MAPK Gene><p38 Mitogen Activated Protein Kinase><p38 Protein Kinase><p38 SAPK><p38-Alpha><p38Alpha><panomics><pathophysiology><pathway><perivascular glial cell><pharmacologic><population aging><predisposing gene><preparations><primary degenerative dementia><promoter><promotor><protein TDP-43><protein TDP43><protein aggregate><protein aggregation><protein homeostasis><proteostasis><receptor><resolutions><response><risk allele><risk gene><risk genotype><risk loci><risk locus><risk variant><senile dementia of the Alzheimer type><shRNA><short hairpin RNA><small hairpin RNA><small molecule><social role><soluble amyloid precursor protein><susceptibility allele><susceptibility locus><susceptibility variant><synapse><synuclein><synucleinopathy><targeted drug therapy><targeted drug treatments><targeted therapeutic><targeted therapeutic agents><targeted therapy><targeted treatment><tau><tau Proteins><tau factor><therapeutic target><therapeutically effective><therapy development><three dimensional><thymus derived lymphocyte><transcription factor><transcription factor NF-AT><transcriptional profile><transcriptional signature><transcriptomics><translation research><translational investigation><translational medicine><treatment development><α synuclein gene><α-syn><α-syn transgenic mouse><α-synuclein><α-synuclein transgenic mouse><τ Proteins>